Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial

Blood (2019) 134 (Supplement_1): 2031.

https://doi.org/10.1182/blood-2019-125646

Published: 2019

Journal Articles

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

Blood (2019) 134 (Supplement_1): 1393.

https://doi.org/10.1182/blood-2019-125257

Published: 2019

Journal Articles

Intensified Dosing of Gemtuzumab Ozogamicin Can be Safely Combined with Induction Chemotherapy in Children with Acute Myeloid Leukaemia (AML) and High Risk Myelodysplasia (MDS)

Brenda Gibson, MD PhD, Aimee E Houlton, BSc, MSc, Andre Baruchel, MD, Guy Leverger, MD PhD, Owen P Smith, MD, Anna Lawson, BSc, Keith Wheatley, DPhil, Pamela R. Kearns, PhD FRCPC

Blood (2018) 132 (Supplement 1): 2681.

https://doi.org/10.1182/blood-2018-99-115899

Published: 2018

Journal Articles

Hydroxycarbamide Plus Aspirin Vs Aspirin Alone in Intermediate Risk Essential Thrombocythemia: Results of the PT-1 International, Prospective, Randomized Clinical Trial

Anna L. Godfrey, BMBCh, PhD MRCP, FRCPath, Peter J Campbell, MD PhD, Cathy MacLean, BSc, MSc, MBA, Georgina Buck, BSc, MSc, Clare L. East, BSc, Julia Cook, BSc, Julie Temple, BSc, Bridget S. Wilkins, MD FRCPath, Keith Wheatley, DPhil, Jyoti Nangalia, MBBChir, MA, MRCP, FRCPath, PhD, Jacob Grinfeld, MBChB, BSc, MRCP, FRCPath, Mary Frances Frances McMullin, MB,Bch BAO, MD FRCPath, Cecily Forsyth, MB BS, Jean-Jacques Kiladjian, MD PhD, Anthony R. Green, FRCP, FRCPath, FMed Sci, Claire N. Harrison, BMBCh, DM, FRCP, FRCPath

Blood (2017) 130 (Supplement 1): 319.

https://doi.org/10.1182/blood.V130.Suppl_1.319.319

Published: 2017

Journal Articles

Results of Inter-B-NHL Ritux 2010 - Phase II Study of DA-EPOCH-R for Children and Adolescents with Primary Mediastinal Large B-Cell Lymphoma (PMLBL) on Behalf of European Intergroup for Childhood Non Hodgkin's Lymphoma (EICNHL) and Children's Oncology Group (COG)

G A Amos Burke, Thomas G. Gross, MD PhD, Marta Pillon, Veronique Minard-colin, Raphael F Delgado, József Zsíros, Anne Uyttebroeck, Jean Michon, Catherine M. Bollard, MD FRACP, FRCPA, Monika Csoka, Donald A Barkauskas, Keith Wheatley, DPhil, Anne Aupérin, Catherine Patte

Blood (2017) 130 (Supplement 1): 4124.

https://doi.org/10.1182/blood.V130.Suppl_1.4124.4124

Published: 2017

Journal Articles

Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

Charles Craddock, MD PhD, Aimee E Houlton, BSc, MSc, Paul Ferguson, MBChB MRCP PhD, Manoj Raghavan, Sonia Fox, Louise Dudley, BSc, MRes, Lynn Swun Quek, FRCPath, DPhil, MBBS, Jamie D. Cavenagh, Michael Dennis, FRCPath, Mary Frances McMullin, MD, Srinivas P Pillai, Richard Kelly, BSc, MD, Shamyla Siddique, Keith Wheatley, DPhil, Paresh Vyas, BM, DPhil, FRCP, FRCPath

Blood (2016) 128 (22): 1065.

https://doi.org/10.1182/blood.V128.22.1065.1065

Published: 2016

Journal Articles

Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myelogenous Leukemia: To Transplant or Not to Transplant? A Systematic Review of International Guidelines.

Kai Hübel, MD, Olaf Weingart, MD, Frauke Naumann, Dr., Julia Bohlius, MD, MScPH, Keith Wheatley, DPhil, Andreas Engert, MD

Blood (2009) 114 (22): 1419.

https://doi.org/10.1182/blood.V114.22.1419.1419

Published: 2009

Journal Articles

Bisphosphonates in Multiple Myeloma. A Systematic Review and Meta Analysis.

Rahul Suresh Mhaskar, MPH, Jasmina Redzepovic, PhD, Keith Wheatley, DPhil, Otavio Clark, MD, PhD, Axel Glasmacher, MD, Ambuj Kumar, MD, MPH, Benjamin Djulbegovic, MD, PhD

Blood (2009) 114 (22): 3858.

https://doi.org/10.1182/blood.V114.22.3858.3858

Published: 2009

Journal Articles

Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial.

Alan K Burnett, Robert K Hills, Donald Milligan, MD, MBChB, Ann E. Hunter, MBBS, FRCP, FRCPath, Anthony H. Goldstone, FRCP, FRCPath, Archie Prentice, MBChB, FRCP, FRCPath, Brenda ES Gibson, Lars Kjeldsen, John AL Yin, Keith Wheatley, DPhil, Nigel H. Russell, MD

Blood (2009) 114 (22): 484.

https://doi.org/10.1182/blood.V114.22.484.484

Published: 2009

Journal Articles

Outcome of Reduced Intensity Allografts in Patients Aged Over 45 Years with Acute Myeloid Leukaemia: Initial Results of the MRC AML15 Trial.

Nigel H. Russell, MD, Andrew J Howman, Keith Wheatley, DPhil, Robert K Hills, Charles Craddock, BM, DPhil, FRCP, FRCPath, Lars Kjeldsen, MD, PhD, John AL Yin, Alan K. Burnett

Blood (2009) 114 (22): 523.

https://doi.org/10.1182/blood.V114.22.523.523

Published: 2009

Journal Articles

Low Dose Ara-C Versus Low Dose Ara-C and Arsenic Trioxide: the UK NCRI AML16 “Pick a Winner” Comparison.

Nigel H. Russell, MD, Robert K Hills, Ann E. Hunter, MBBS, FRCP, FRCPath, Donald Milligan, MD, MBChB, William J. Kell, MD, MB, Keith Wheatley, DPhil, Mary Frances McMullin, John AL Yin, David T. Bowen, MD, A. Burnett, MD, FRCP

Blood (2009) 114 (22): 486.

https://doi.org/10.1182/blood.V114.22.486.486

Published: 2009

Journal Articles

Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 “Pick a Winner” Comparison

Alan K. Burnett, MD, FRCP, Robert Hills, MA, MSc, DPhil, Donald Milligan, MD, MBChB, William J. Kell, MD, MB, Keith Wheatley, DPhil, Andres E. Virchis, FRCP, FRCPath, Nigel H. Russell, MD

Blood (2008) 112 (11): 2962.

https://doi.org/10.1182/blood.V112.11.2962.2962

Published: 2008

Journal Articles

Predictive Value of Minimal Residual Disease (MRD) Monitoring by RQ-PCR in WT1 Positive Patients Entered in the UK MRC AML-15 Trial

John Liu-Yin, FRCP, FRCPath, Michelle Sale, MSc, Sarah Daly, PhD, Robert Hills, MA, MSc, DPhil, Keith Wheatley, DPhil, Alan K. Burnett, MD, FRCP

Blood (2008) 112 (11): 697.

https://doi.org/10.1182/blood.V112.11.697.697

Published: 2008

Journal Articles

The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial

Rosemary Gale, PhD, Robert Hills, MA, MSc, DPhil, Claire Green, Yashma Patel, Amanda Gilkes, Michelle Lazenby, Keith Wheatley, DPhil, David C. Linch, FRCP, Alan Burnett

Blood (2008) 112 (11): 554.

https://doi.org/10.1182/blood.V112.11.554.554

Published: 2008

Journal Articles

Impact of Platelet Glycoprotein Polymorphisms upon Clinical Events in Essential Thrombocythaemia Patients Enrolled in the PT1 Trial.

Susan E. Robinson, MSc, MRCPath, Peter J. Campbell, FRCPA, PhD, Georgina Buck, MSc, Keith Wheatley, DPhil, Jacqueline A. Cutler, BSc, Ruth B. Wheeler, BSc, PhD, Savita Rangarajan, FRCP, FRCPath, Beverley J. Hunt, RCPath, Anthony R. Green, FRCPath, FMedSci, Claire N. Harrison, MD, FRCPath

Blood (2007) 110 (11): 2543.

https://doi.org/10.1182/blood.V110.11.2543.2543

Published: 2007

Journal Articles

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

Alan K. Burnett, MD, Robert K. Hills, DPhil, David Grimwade, MD, Anthony H. Goldstone, MD, Ann Hunter, MD, Don Milligan, MD, Archie G. Prentice, MD, Nigel H. Russell, MD, Keith Wheatley, DPhil

Blood (2007) 110 (11): 589.

https://doi.org/10.1182/blood.V110.11.589.589

Published: 2007

Journal Articles

A Sensitive Risk Score for Directing Treatment in Younger Patients with AML.

Alan K. Burnett, MD, FRCPath, FRCP, Robert K. Hills, MA, MSc, DPhil, Keith Wheatley, DPhil, Anthony H. Goldstone, MRCP, MRCPath, FRCP, Archie G. Prentice, MB, ChB, FRCP, FRCPath, Donald Milligan, MD, FRCP, FRCPath

Blood (2006) 108 (11): 18.

https://doi.org/10.1182/blood.V108.11.18.18

Published: 2006

Journal Articles

The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial.

Alan K. Burnett, MD, FRCPath, FRCP, William J. Kell, MD, Anthony H. Goldstone, DM, Donald Milligan, FRCP, Ann Hunter, FRCP, Archie G. Prentice, FRCP, Nigel H. Russell, MD, Brenda Gibson, FRCP, Keith Wheatley, DPhil, Robert K. Hills, MA, MSc, DPhil

Blood (2006) 108 (11): 13.

https://doi.org/10.1182/blood.V108.11.13.13

Published: 2006

Journal Articles

Prognostic Factors in Older AML Patients Receiving Intensive and Non-Intensive Therapy: Analysis of the UK AML11 and AML14 Trials.

Keith Wheatley, DPhil, Cassey L. Brookes, MSc, Robert K. Hills, DPhil, Anthony H. Goldstone, FRCP, Donald W. Milligan, MD, Archie G. Prentice, Anthony V. Moorman, PhD, Alan K. Burnett

Blood (2005) 106 (11): 674.

https://doi.org/10.1182/blood.V106.11.674.674

Published: 2005

Journal Articles

Meta-Analyses of Randomised Controlled Trials (RCT) of Warfarin and Low Molecular Weight Heparin (LMWH) for the Prevention of Venous Thromboembolism (VTE) and Death in Cancer Patients.

Keith Wheatley, DPhil, Laura E. Gross, DPhil, Robert K. Hills, DPhil, Annie M. Young, BSc, RGN

Blood (2005) 106 (11): 909.

https://doi.org/10.1182/blood.V106.11.909.909

Published: 2005

NARROW

The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

Intensified Dosing of Gemtuzumab Ozogamicin Can be Safely Combined with Induction Chemotherapy in Children with Acute Myeloid Leukaemia (AML) and High Risk Myelodysplasia (MDS)

Hydroxycarbamide Plus Aspirin Vs Aspirin Alone in Intermediate Risk Essential Thrombocythemia: Results of the PT-1 International, Prospective, Randomized Clinical Trial

Results of Inter-B-NHL Ritux 2010 - Phase II Study of DA-EPOCH-R for Children and Adolescents with Primary Mediastinal Large B-Cell Lymphoma (PMLBL) on Behalf of European Intergroup for Childhood Non Hodgkin's Lymphoma (EICNHL) and Children's Oncology Group (COG)

Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myelogenous Leukemia: To Transplant or Not to Transplant? A Systematic Review of International Guidelines.

Bisphosphonates in Multiple Myeloma. A Systematic Review and Meta Analysis.

Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial.

Outcome of Reduced Intensity Allografts in Patients Aged Over 45 Years with Acute Myeloid Leukaemia: Initial Results of the MRC AML15 Trial.

Low Dose Ara-C Versus Low Dose Ara-C and Arsenic Trioxide: the UK NCRI AML16 “Pick a Winner” Comparison.

Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 “Pick a Winner” Comparison

Predictive Value of Minimal Residual Disease (MRD) Monitoring by RQ-PCR in WT1 Positive Patients Entered in the UK MRC AML-15 Trial

The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial

Impact of Platelet Glycoprotein Polymorphisms upon Clinical Events in Essential Thrombocythaemia Patients Enrolled in the PT1 Trial.

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

A Sensitive Risk Score for Directing Treatment in Younger Patients with AML.

The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial.

Prognostic Factors in Older AML Patients Receiving Intensive and Non-Intensive Therapy: Analysis of the UK AML11 and AML14 Trials.

Meta-Analyses of Randomised Controlled Trials (RCT) of Warfarin and Low Molecular Weight Heparin (LMWH) for the Prevention of Venous Thromboembolism (VTE) and Death in Cancer Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only